Navigation Links
Two Additional Private Payers Provide Coverage for Posterior Tibial Nerve Stimulation Delivered Using the Uroplasty Urgent® PC Neuromodulation System
Date:7/18/2011

therlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our focus is the continued commercialization of our Urgent PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.  We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.  For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking InformationThis press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.For Further Information:
Uroplasty, Inc.
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, Treasurer
952.426.6140 EVC Group
Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820
Chris Gale (Media), 646.201.5431
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new ... provides key market data on the BRIC Gynecological ... of US dollars, volume (in units) and average ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and ...
(Date:9/17/2014)... YORK , Sept. 17, 2014 /PRNewswire/ ... growth during the last decade due to ... natural calamities and technological advancements. This BCC ... within various segments of the ambulance and ... transportation equipment, blood and hemorrhage control devices, ...
(Date:9/17/2014)... YORK , Sept. 17, 2014 Pomerantz ... PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NASDAQ: ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... BioPharma and certain of its officers and/or directors have ... Act of 1934.  On September 17, ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
... studies affirmed the clinical benefits of,ACTEMRA -, ... Phase III studies,showed that patients who suffer from ... achieved significant improvements in signs and,symptoms when treated ... compared with methotrexate alone. The final results of,both ...
... PTC124 Highlighted in Multiple Presentations at North ... N.J. and ORLANDO, Fla., Oct. 24 ... from a randomized,Phase 2a European study demonstrated ... statistically significant improvements,in the chloride channel function ...
Cached Medicine Technology:ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 2PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 3PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 4PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 5PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 6
(Date:9/18/2014)... (PRWEB) September 18, 2014 According to the ... from eczema, with many of them being children. In fact, ... diagnosed as babies and children. The millions of children who ... be brought on by eczema. A new book has been ... they are and to find relief from the condition over ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 SpineFrontier ... team and surgeon partners in Less Exposure Surgery ... SpineFrontier, Tamara authored an extensive education curriculum and ... Masters in Science in Organizational Leadership, and has ... for eleven years. Bringing her to the team ...
(Date:9/18/2014)... 18, 2014 First Choice Emergency ... rooms in the United States, named Douglas J. Harrison, ... City-Lakes facility. , “We are pleased to welcome ... director of our new Missouri City-Lakes facility,” said Dr. ... Emergency Room. , Dr. Harrison received his undergraduate ...
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
(Date:9/17/2014)... September 18, 2014 Recently, BambooIndustry.com, an outstanding ... of bamboo floorings . There are more than 1000 ... has launched a big promotion for these useful items. Each ... 30 % off. , “We are very proud to ... to say, all these items are made with natural materials ...
Breaking Medicine News(10 mins):Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2
... a newly developed drug, which is aimed at a particular ... tumour growth, is active in patients with advanced cancers and, ... The drug, ACE-041, targets a different molecular pathway to ... treat cancer. Results from a phase I clinical ...
... surgery should receive a risk assessment before their procedure ... in the legs or lungs, according to research at ... that 1 in 9 patients at highest risk based ... clot-preventing medications after surgery. Published in the November ...
... into mice with metastatic melanoma has resulted in permanent ... cancer, according to an article to be published in ... Clinical Investigation . The online version is now available. ... modified lentivirus to introduce a potent anti-melanoma T cell ...
... federal agencies recently cosponsored a set of expert work ... to psychological adjustment and traumatic brain injury (TBI). ... behavioral neuroscience at Boston University School of Medicine, chaired ... Dr. Kaloupek,s work at the National Center for PTSD ...
... of six national participants in a pilot study that ... families have a smoother care experience and better outcomes ... to reliably adhere to best practice standards. The ... the Society of Thoracic Surgeons (STS) will study clinician ...
... have been stymied for years over the fact that people ... response to the pathogen antibodies that turn out to ... Medical Center can explain why: Some of the earliest and ... the virus until after it,s already invaded a healthy cell. ...
Cached Medicine News:Health News:Researchers find new target for stopping tumors developing their own blood supply 2Health News:Researchers find new target for stopping tumors developing their own blood supply 3Health News:Assessment tool predicts blood clot risk after plastic surgery 2Health News:Assessment tool predicts blood clot risk after plastic surgery 3Health News:Gene therapy for metastatic melanoma in mice produces complete remission 2Health News:Researchers identify PTSD measures for use in traumatic brain injury research 2Health News:Lung cancer patients are the centerpiece for Northwestern medicine quality of care study 2Health News:Why so many antibodies fail to protect against HIV infection 2
... When it comes to ventral hernia repair, ... While a hernia is often best treated with ... concern about the risk of bowel adhesions to ... mesh, an innovative product designed to meet the ...
... dual-sided ePTFE mesh designed for ventral hernia repair. ... to minimize visceral attachment to the prosthesis. On ... to promote tissue growth. This ingrowth side has ... is nearly equivalent to polypropylene mesh. Bard Dulex ...
... Since its introduction in 1958, Bard mesh ... other products are compared. Bard mesh was ... first developed the "tension-free" hernia repair many ... "a safe and ideal" substance for permanent ...
... Modified Kugel patch repair is a minimally ... through a small 4-6 cm incision and ... repair performed through an open, anterior approach ... regional anesthesia.,The Modified Kugel patch is a ...
Medicine Products: